You can reach her at sdecrescenzo@xconomy.com. Servier is licensing cancer drug treatment software from US start-up CureMatch. The latter’s PreciGENE guide helps oncologists configure suitable combinations of drugs to give patients based on cancer DNA mutations. In a recent interview with Quartz, the company’s CEO and co-founder The undisclosed deal sees Servier gain exclusive rights to sell access to CureMatch’s platform across its worldwide network of clinics and hospitals. CureMatch will receive help expanding sales and marketing, while receiving assistance in its clinical trial and software development programmes.
Servier is licensing cancer drug treatment software from US start-up CureMatch. The latter’s PreciGENE guide helps oncologists configure suitable combinations of drugs to give patients based on cancer DNA mutations. In a recent interview with Quartz, the company’s CEO and co-founder The undisclosed deal sees Servier gain exclusive rights to sell access to CureMatch’s platform across its worldwide network of clinics and hospitals. CureMatch will receive help expanding sales and marketing, while receiving assistance in its clinical trial and software development programmes.